Biomarkers in critical illness: have we made progress?
Biomarkers have emerged as exemplary key players in translational medicine. Many have been assessed for timely recognition, early treatment, and adequate follow-up for a variety of pathologies. Biomarker sensitivity has improved considerably over the last years but specificity remains poor, in parti...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Online |
| Language: | English |
| Published: |
Dove Medical Press
2016
|
| Online Access: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5074734/ |
| id |
pubmed-5074734 |
|---|---|
| recordtype |
oai_dc |
| spelling |
pubmed-50747342016-10-31 Biomarkers in critical illness: have we made progress? Honore, Patrick M Jacobs, Rita Hendrickx, Inne De Waele, Elisabeth Van Gorp, Viola Joannes-Boyau, Olivier De Regt, Jouke Boer, Willem Spapen, Herbert D Review Biomarkers have emerged as exemplary key players in translational medicine. Many have been assessed for timely recognition, early treatment, and adequate follow-up for a variety of pathologies. Biomarker sensitivity has improved considerably over the last years but specificity remains poor, in particular when two “marker-sensitive” conditions overlap in one patient. Biomarker research holds an enormous potential for diagnostic and prognostic purposes in postoperative and critically ill patients who present varying degrees of inflammation, infection, and concomitant (sub)acute organ dysfunction or failure. Despite a remarkable progress in development and testing, biomarkers are not yet ready for routine use at the bedside. Dove Medical Press 2016-10-17 /pmc/articles/PMC5074734/ /pubmed/27799811 http://dx.doi.org/10.2147/IJNRD.S113219 Text en © 2016 Honore et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. |
| repository_type |
Open Access Journal |
| institution_category |
Foreign Institution |
| institution |
US National Center for Biotechnology Information |
| building |
NCBI PubMed |
| collection |
Online Access |
| language |
English |
| format |
Online |
| author |
Honore, Patrick M Jacobs, Rita Hendrickx, Inne De Waele, Elisabeth Van Gorp, Viola Joannes-Boyau, Olivier De Regt, Jouke Boer, Willem Spapen, Herbert D |
| spellingShingle |
Honore, Patrick M Jacobs, Rita Hendrickx, Inne De Waele, Elisabeth Van Gorp, Viola Joannes-Boyau, Olivier De Regt, Jouke Boer, Willem Spapen, Herbert D Biomarkers in critical illness: have we made progress? |
| author_facet |
Honore, Patrick M Jacobs, Rita Hendrickx, Inne De Waele, Elisabeth Van Gorp, Viola Joannes-Boyau, Olivier De Regt, Jouke Boer, Willem Spapen, Herbert D |
| author_sort |
Honore, Patrick M |
| title |
Biomarkers in critical illness: have we made progress? |
| title_short |
Biomarkers in critical illness: have we made progress? |
| title_full |
Biomarkers in critical illness: have we made progress? |
| title_fullStr |
Biomarkers in critical illness: have we made progress? |
| title_full_unstemmed |
Biomarkers in critical illness: have we made progress? |
| title_sort |
biomarkers in critical illness: have we made progress? |
| description |
Biomarkers have emerged as exemplary key players in translational medicine. Many have been assessed for timely recognition, early treatment, and adequate follow-up for a variety of pathologies. Biomarker sensitivity has improved considerably over the last years but specificity remains poor, in particular when two “marker-sensitive” conditions overlap in one patient. Biomarker research holds an enormous potential for diagnostic and prognostic purposes in postoperative and critically ill patients who present varying degrees of inflammation, infection, and concomitant (sub)acute organ dysfunction or failure. Despite a remarkable progress in development and testing, biomarkers are not yet ready for routine use at the bedside. |
| publisher |
Dove Medical Press |
| publishDate |
2016 |
| url |
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5074734/ |
| _version_ |
1613693110896820224 |